Shi Liang, Meng Qiyi, Tong Li, Li Hongxia, Dong Yujie, Su Chongyu, Liu Zhe
Department of Medical Oncology, Beijing Chest Hospital, Beijing Tuberculosis and Thoracic Tumor Research Institute, Capital Medical University, Beijing, China.
Department of Pathology, Beijing Chest Hospital, Beijing Tuberculosis and Thoracic Tumor Research Institute, Capital Medical University, Beijing, China.
Front Oncol. 2022 Oct 14;12:956755. doi: 10.3389/fonc.2022.956755. eCollection 2022.
Several randomized studies have shown that the combination of programmed cell death 1 (PD-1) inhibitor and chemotherapy is efficacious as a treatment for advanced non-small-cell lung cancer (NSCLC). However, in the neoadjuvant setting, there is scarce evidence of the effectiveness and safety of the combinations in squamous NSCLC. We conducted a retrospective study to evaluate neoadjuvant PD-1 inhibitor plus chemotherapy in resectable squamous NSCLC.
Patients from Beijing Chest Hospital, Capital Medical University, between October 2019 and October 2021, treated with PD-1 inhibitors and chemotherapy for resectable squamous NSCLC were retrospectively studied. The primary objectives were to assess the pathological tumor response and safety of neoadjuvant PD-1 inhibitors and chemotherapy.
63 patients with resectable squamous NSCLC stage IIA-IIIB were included. Two to four cycles of PD-1 inhibitors (37 cases with camrelizumab, 11 cases with toripalimab, 8 cases with tislelizumab, and 7 cases with sintilimab) and chemotherapy were administered prior to surgery. 42 patients (66.7%) achieved a major pathologic response (MPR), including 25 (39.7%) with a pathologic complete response (pCR). Twenty-one patients (33.3%) experienced grade 3 neoadjuvant treatment-related adverse events (TRAEs), and no patient had grade 4 or 5 TRAE.
Neoadjuvant PD-1 inhibitors and chemotherapy are feasible therapies for resectable squamous NSCLC. It was associated with a 66.7% MPR rate, 39.7% pCR rate, and tolerable toxicity.
多项随机研究表明，程序性细胞死亡蛋白1（PD-1）抑制剂与化疗联合使用对晚期非小细胞肺癌（NSCLC）有效。然而，在新辅助治疗中，关于该联合方案在鳞状NSCLC中的有效性和安全性的证据很少。我们进行了一项回顾性研究，以评估新辅助PD-1抑制剂联合化疗用于可切除鳞状NSCLC的疗效。
回顾性研究2019年10月至2021年10月在首都医科大学附属北京胸科医院接受PD-1抑制剂和化疗治疗的可切除鳞状NSCLC患者。主要目的是评估新辅助PD-1抑制剂和化疗的病理肿瘤反应及安全性。
纳入63例IIA-IIIB期可切除鳞状NSCLC患者。术前给予2至4个周期PD-1抑制剂（37例卡瑞利珠单抗、11例特瑞普利单抗、8例替雷利珠单抗和7例信迪利单抗）联合化疗。42例患者（66.7%）达到主要病理缓解（MPR），其中25例（39.7%）达到病理完全缓解（pCR）。21例患者（33.3%）发生3级新辅助治疗相关不良事件（TRAEs），无患者发生≥4级TRAEs。
新辅助PD-1抑制剂联合化疗是可切除鳞状NSCLC的可行治疗方案。该方案MPR率为66.7%，pCR率为39.7%，毒性可耐受。
